Cited 34 times in
Phase I/II trial of helical IMRT-based stereotactic body radiotherapy for hepatocellular carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김준원 | - |
dc.contributor.author | 성진실 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2019-07-11T03:16:09Z | - |
dc.date.available | 2019-07-11T03:16:09Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 1590-8658 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/169894 | - |
dc.description.abstract | BACKGROUND: To report the results of a phase I/II study of helical IMRT-based stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC). METHODS: Eligibility included Child-Turcotte-Pugh class A or B, ≤3 lesions, and cumulative tumor diameter ≤6 cm. Dose was escalated from 36 Gy to 60 Gy delivered in 4 fractions. Grade ≥3 gastrointestinal toxicities (CTCAE v3.0) or radiation-induced liver disease defined dose-limiting toxicity (DLT). RESULTS: Thirty-two patients were enrolled: seven in dose levels 1-2 (36-44 Gy) and 25 in levels 3-4 (42-60 Gy). Failures included 1 local, 14 outfield intrahepatic, 2 distant, 1 concurrent local and outfield, 1 concurrent outfield and distant, and 1 concurrent local, outfield, and distant. Nine had grade 3 hematologic toxicities and 5 had grade 2 hepatic toxicities; no patient experienced DLT. Two-year local control (LFFS), outfield intrahepatic control (OutFFS), and overall survival (OS) rates were 80.9%, 46.7%, and 81.3%, respectively. Dose levels 3-4 and pre-radiotherapy multi-segment recurrence were independent prognostic factors for LFFS and OutFFS, respectively. Two-year LFFS, OutFFS, and OS were significantly higher for patients who were treated with dose-levels 3/4 for tumor(s) involving single segment compared with the rest of the patients. CONCLUSIONS: Helical IMRT-based SBRT was safe and effective, and patients with multi-segment recurrences prior to SBRT need to be closely followed. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Elsevier | - |
dc.relation.isPartOf | DIGESTIVE AND LIVER DISEASE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Phase I/II trial of helical IMRT-based stereotactic body radiotherapy for hepatocellular carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Jun Won Kim | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Kwang-Hyub Han | - |
dc.contributor.googleauthor | Jinsil Seong | - |
dc.identifier.doi | 10.1016/j.dld.2018.11.004 | - |
dc.contributor.localId | A00385 | - |
dc.contributor.localId | A00958 | - |
dc.contributor.localId | A01956 | - |
dc.contributor.localId | A04268 | - |
dc.relation.journalcode | J00735 | - |
dc.identifier.eissn | 1878-3562 | - |
dc.identifier.pmid | 30503296 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S1590865818312234 | - |
dc.subject.keyword | Helical intensity-modulated radiotherapy | - |
dc.subject.keyword | Hepatocellular carcinoma | - |
dc.subject.keyword | Phase I/II trial | - |
dc.subject.keyword | Stereotactic body radiotherapy | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | 김도영 | - |
dc.contributor.affiliatedAuthor | 김준원 | - |
dc.contributor.affiliatedAuthor | 성진실 | - |
dc.contributor.affiliatedAuthor | 한광협 | - |
dc.citation.volume | 51 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 445 | - |
dc.citation.endPage | 451 | - |
dc.identifier.bibliographicCitation | DIGESTIVE AND LIVER DISEASE, Vol.51(3) : 445-451, 2019 | - |
dc.identifier.rimsid | 62573 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.